Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors

Bain Capital Life Sciences and GordonMD® Global Investments LP join existing investors Proceeds to support clinical development of novel fully human anti-CD19 CAR T-cell therapies for autoimmune diseases EMERYVILLE, Calif., Aug. 3, 2023 /PRNewswire/ — Kyverna Therapeutics (“Kyverna”), a…

Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks